{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:55:24Z","timestamp":1789631724726,"version":"build-2803163510"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The activities of daptomycin, a cyclic lipopeptide, and eight other agents were determined against 338 strains of gram-positive anaerobic bacteria and corynebacteria by the NCCLS reference agar dilution method with supplemented brucella agar for the anaerobes and Mueller-Hinton agar for the corynebacteria. The daptomycin MICs determined on Ca\n            <jats:sup>2+<\/jats:sup>\n            -supplemented (50 mg\/liter) brucella agar plates were one- to fourfold lower than those determined in unsupplemented media. Daptomycin was highly active (MICs, \u22642 \u03bcg\/ml) against many strains including 36 of 37 peptostreptococci, 37 of 48 isolates of the\n            <jats:italic>Eubacterium<\/jats:italic>\n            group, and all strains of\n            <jats:italic>Propionibacterium<\/jats:italic>\n            spp.,\n            <jats:italic>Clostridium perfringens<\/jats:italic>\n            ,\n            <jats:italic>Clostridium difficile<\/jats:italic>\n            , and other\n            <jats:italic>Clostridium<\/jats:italic>\n            spp. It was fourfold or greater more active than vancomycin against\n            <jats:italic>Clostridium innocuum<\/jats:italic>\n            and 16 of 34 strains of vancomycin-resistant lactobacilli. Three strains of\n            <jats:italic>C. difficile<\/jats:italic>\n            for which quinupristin-dalfopristin and linezolid MICs were &gt;8 \u03bcg\/ml were inhibited by &lt;1 \u03bcg of daptomycin per ml. Daptomycin MICs were \u22654 \u03bcg\/ml for most strains of\n            <jats:italic>Clostridium clostridioforme<\/jats:italic>\n            ,\n            <jats:italic>Clostridium paraputrificum<\/jats:italic>\n            ,\n            <jats:italic>Clostridium tertium<\/jats:italic>\n            , and\n            <jats:italic>Clostridium ramosum<\/jats:italic>\n            ; the isolates were generally more resistant to other antimicrobials. Daptomycin was two- to fourfold less active against\n            <jats:italic>Actinomyces<\/jats:italic>\n            spp. than vancomycin, quinupristin-dalfopristin, or linezolid. Twenty-nine of 31 strains of\n            <jats:italic>Corynebacterium<\/jats:italic>\n            spp., including\n            <jats:italic>Corynebacterium jeikeium<\/jats:italic>\n            ,\n            <jats:italic>Corynebacterium amycolatum<\/jats:italic>\n            , and\n            <jats:italic>Corynebacterium pseudodiphtheriticum<\/jats:italic>\n            , were inhibited by \u22640.25 \u03bcg of daptomycin per ml. For two strains of \u201c\n            <jats:italic>Corynebacterium aquaticum<\/jats:italic>\n            ,\u201d 8 \u03bcg of daptomycin per ml was required for inhibition. Daptomycin demonstrated very good activities against a broad range of gram-positive organisms including vancomycin-resistant\n            <jats:italic>C. innocuum<\/jats:italic>\n            and lactobacillus strains and quinupristin-dalfopristin- and linezolid-resistant\n            <jats:italic>C. difficile<\/jats:italic>\n            strains.\n          <\/jats:p>","DOI":"10.1128\/aac.47.1.337-341.2003","type":"journal-article","created":{"date-parts":[[2002,12,24]],"date-time":"2002-12-24T04:39:08Z","timestamp":1040704748000},"page":"337-341","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":73,"title":["In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31\n            <i>Corynebacterium<\/i>\n            Clinical Isolates"],"prefix":"10.1128","volume":"47","author":[{"given":"Ellie J. C.","family":"Goldstein","sequence":"first","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica, California 90404"},{"name":"School of Medicine, University of California, Los Angeles, Los Angeles, California 90073"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Citron","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica, California 90404"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Vreni","family":"Merriam","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica, California 90404"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi A.","family":"Warren","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica, California 90404"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrin L.","family":"Tyrrell","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica, California 90404"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen T.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica, California 90404"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.11.2282"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.12.3209-3215.1995"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1919-1922.2001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jac\/26.5.627","volume":"26","year":"1990","unstructured":"Bartoloni, A., M. G. Colao, A. Orsi, R. Dei, E. Giganti, and F. Parenti. 1990. In vitro activity of vancomycin, teichoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enetrococci, and Clostridium difficile. J. Antimicrob. Chemother.26:627-633.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.5.741"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.5.788"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1135"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.4.532"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.3.461"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00164-4"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02013071"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2307\/30140952"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.3.455"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1652"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.4.625"},{"key":"e_1_3_2_17_2","unstructured":"Murray P. R. E. J. Baron M. A. Pfaller F. C. Tenover and R. H. Yolken (ed.). 1999. Manual of clinical microbiology 7th ed. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_18_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Method for dilution antimicrobial susceptibility testing for bacteria that grow aerobically 5th ed. Approved standard. NCCLS publication M7-A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_19_2","unstructured":"National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria 5th ed. Approved standard. NCCLS publication M11-A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"189.","DOI":"10.1007\/BF02018207","volume":"6","year":"1987","unstructured":"Nord, C. E., A. Lindmark, and I. Persson. 1987. Susceptibility of Clostridium difficile to LY146032. Eur. J. Clin. Microbiol.6:189.","journal-title":"Eur. J. Clin. Microbiol."},{"key":"e_1_3_2_21_2","first-page":"686.","volume":"6","year":"1987","unstructured":"Nord, C. E., A. Lindmark, and I. Persson. 1987. LY146032 treatment of Clostridium difficile colitis in hamsters. Eur. J. Clin. Microbiol.6:686.","journal-title":"Eur. J. Clin. Microbiol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0732-8893(88)90100-9","volume":"9","year":"1988","unstructured":"Silva, M., N. V. Jacobus, and S. L. Gorbach. 1988. In vitro activity of LY 146032 against gram-positive bacteria. Diagn. Microbiol. Infect. Dis.9:79-85.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1799-1802.2001"},{"key":"e_1_3_2_24_2","unstructured":"Summanen P. E. J. Baron D. M. Citron C. A. Strong H. M. Wexler and S. M. Finegold. 1993. Wadsworth anaerobic bacteriology manual 5th ed. Star Publishing Co. Belmont Calif."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.4.523"}],"updated-by":[{"DOI":"10.1128\/aac.47.4.1486.2003","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000}}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.1.337-341.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.1.337-341.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:56:02Z","timestamp":1645466162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.1.337-341.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1128\/AAC.47.1.337-341.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.1.337-341.2003","relation":{"correction":[{"id-type":"doi","id":"10.1128\/AAC.47.4.1486.2003","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2002-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-10-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}